Q-omics provides the consensus-scored CCDC184 profile across patient tissues and cancer cell-line models. CCDC184 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CCDC184 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, CCDC184 RNA expression shows 14,834 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight MESO, KICH, and UCEC as cancer lineages where CCDC184 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC184 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC184 survival associations across molecular data types. CCDC184 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC184 RNA expression–survival associations across cancer types. High CCDC184 expression shows unfavorable associations in MESO, UVM, BLCA and ACC, but favorable associations in LUAD and LIHC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CCDC184 RNA expression.
This table summarizes CCDC184 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC184. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC184 shows lower tumor expression in KICH, BRCA, COAD, UCEC and STAD and higher tumor expression in CHOL. The KICH box plot shows higher CCDC184 RNA expression in normal versus tumor tissue (log2 FC = −1.488, t-test p < 0.001).
This table shows molecular features associated with CCDC184 in patient tissues and cancer cell lines. In patient samples, CCDC184 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC184 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
